DB:TF2

Stock Analysis Report

Executive Summary

Takara Bio Inc., together with its subsidiaries, operates as a biotechnology company in Japan and internationally.

Snowflake

Fundamentals

Flawless balance sheet with reasonable growth potential.


Similar Companies

Share Price & News

How has Takara Bio's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: TF2 has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

-9.8%

TF2

-2.3%

DE Biotechs

0.03%

DE Market


1 Year Return

-13.0%

TF2

-6.9%

DE Biotechs

9.9%

DE Market

Return vs Industry: TF2 underperformed the German Biotechs industry which returned -6.9% over the past year.

Return vs Market: TF2 underperformed the German Market which returned 9.9% over the past year.


Shareholder returns

TF2IndustryMarket
7 Day-9.8%-2.3%0.03%
30 Day-6.2%-3.1%4.4%
90 Day-13.1%-9.6%13.6%
1 Year-12.7%-13.0%-6.7%-6.9%13.4%9.9%
3 Year35.7%34.7%52.7%50.8%25.6%14.6%
5 Year62.5%60.9%5.0%2.7%36.9%18.2%

Price Volatility Vs. Market

How volatile is Takara Bio's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Takara Bio undervalued compared to its fair value and its price relative to the market?

61.56x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: TF2 (€16.6) is trading above our estimate of fair value (€13.58)

Significantly Below Fair Value: TF2 is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: TF2 is poor value based on its PE Ratio (61.6x) compared to the Biotechs industry average (29.8x).

PE vs Market: TF2 is poor value based on its PE Ratio (61.6x) compared to the German market (19.5x).


Price to Earnings Growth Ratio

PEG Ratio: TF2 is poor value based on its PEG Ratio (3x)


Price to Book Ratio

PB vs Industry: TF2 is overvalued based on its PB Ratio (3.8x) compared to the DE Biotechs industry average (3.1x).


Next Steps

Future Growth

How is Takara Bio forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

20.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: TF2's forecast earnings growth (20.3% per year) is above the savings rate (0.2%).

Earnings vs Market: TF2's earnings (20.3% per year) are forecast to grow faster than the German market (12.5% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: TF2's revenue (9.4% per year) is forecast to grow faster than the German market (4.8% per year).

High Growth Revenue: TF2's revenue (9.4% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: TF2's Return on Equity is forecast to be low in 3 years time (11.1%).


Next Steps

Past Performance

How has Takara Bio performed over the past 5 years?

30.1%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: TF2 has high quality earnings.

Growing Profit Margin: TF2's current net profit margins (11.5%) are higher than last year (10.6%).


Past Earnings Growth Analysis

Earnings Trend: TF2's earnings have grown significantly by 30.1% per year over the past 5 years.

Accelerating Growth: TF2's earnings growth over the past year (6.9%) is below its 5-year average (30.1% per year).

Earnings vs Industry: TF2 earnings growth over the past year (6.9%) exceeded the Biotechs industry 5.4%.


Return on Equity

High ROE: TF2's Return on Equity (6.2%) is considered low.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Takara Bio's financial position?


Financial Position Analysis

Short Term Liabilities: TF2's short term assets (¥34.1B) exceeds its short term liabilities (¥4.8B)

Long Term Liabilities: TF2's short term assets (34.1B) exceeds its long term liabilities (1.5B)


Debt to Equity History and Analysis

Debt Level: TF2 is debt free.

Reducing Debt: TF2 has no debt compared to 5 years ago when its debt to equity ratio was 0.6%.

Debt Coverage: TF2 has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: TF2 has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet

Inventory Level: TF2 has a high level of physical assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if TF2's debt is covered by short term assets.


Next Steps

Dividend

What is Takara Bio's current dividend yield, its reliability and sustainability?

0.39%

Current Dividend Yield


Upcoming Dividend Payment

Purchase Takara Bio before the 'Buy Limit' to receive their next dividend payment.


Dividend Yield vs Market

company0.4%marketbottom25%1.3%markettop25%3.7%industryaverage1.1%forecastin3Years0.5%

Current dividend yield vs market & industry

Notable Dividend: TF2's dividend (0.39%) isn’t notable compared to the bottom 25% of dividend payers in the German market (1.33%).

High Dividend: TF2's dividend (0.39%) is low compared to the top 25% of dividend payers in the German market (3.66%).


Stability and Growth of Payments

Stable Dividend: TF2 is not paying a notable dividend for the German market, therefore no need to check if payments are stable.

Growing Dividend: TF2 is not paying a notable dividend for the German market, therefore no need to check if payments are increasing.


Current Payout to Shareholders

Dividend Coverage: TF2 is not paying a notable dividend for the German market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of TF2's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

What is the CEO of Takara Bio's salary, the management and board of directors tenure and is there insider trading?

3.9yrs

Average board tenure


CEO

Koichi Nakao (57yo)

0yrs

Tenure

0

Mr. Koichi Nakao has been the President of Takara Bio Inc. since May 2009 and serves as its Chief Executive Officer. Mr. Nakao served as the Chief Operating Officer of Takara Bio Inc. He serves as the Chai ...


Board Age and Tenure

3.9yrs

Average Tenure

63yo

Average Age

Experienced Board: TF2's board of directors are considered experienced (3.9 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Management Team

  • Hisashi Ohmiya (76yo)

    Chairman of the Board

    • Tenure: 17.6yrs
  • Koichi Nakao (57yo)

    CEO, President & Representative Director

    • Tenure: 0yrs
  • Carol Lou

    President

    • Tenure: 0yrs
  • Shuichiro Matsuzaki (63yo)

    Executive VP & Director

    • Tenure: 5.4yrs
  • Andrew Farmer

    Head of Research and Development

    • Tenure: 0yrs
  • Yoh Hamaoka

    Senior Executive Officer

    • Tenure: 0yrs
  • Tsuyoshi Miyamura

    Senior Executive Officer & Director

    • Tenure: 1.4yrs
  • Kazuki Yamamoto

    Senior Executive Officer

    • Tenure: 0yrs
  • Masanari Kitagawa

    Executive Officer

    • Tenure: 0yrs
  • Masaharu Watabe

    Senior Executive Officer

    • Tenure: 0yrs

Board Members

  • Hisashi Ohmiya (76yo)

    Chairman of the Board

    • Tenure: 17.6yrs
  • Koichi Nakao (57yo)

    CEO, President & Representative Director

    • Tenure: 0yrs
  • Shuichiro Matsuzaki (63yo)

    Executive VP & Director

    • Tenure: 5.4yrs
  • Tsuyoshi Miyamura

    Senior Executive Officer & Director

    • Tenure: 1.4yrs
  • Masahide Tamaki

    Standing Audit & Supervisory Board Members

    • Tenure: 0.8yrs
  • Jawaharlal Bhatt

    External Director

    • Tenure: 9.4yrs
  • Junichi Mineno

    Director

    • Tenure: 5.4yrs
  • Kazuko Kimura

    Outside Director

    • Tenure: 0.8yrs
  • Nobuko Kawashima

    External Director

    • Tenure: 3.4yrs
  • Masanobu Kimura

    Senior Executive Officer & Director

    • Tenure: 2.4yrs

Company Information

Takara Bio Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Takara Bio Inc.
  • Ticker: TF2
  • Exchange: DB
  • Founded: 2002
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: JP¥246.972b
  • Listing Market Cap: JP¥2.054b
  • Shares outstanding: 120.42m
  • Website: https://www.takara-bio.com

Number of Employees


Location

  • Takara Bio Inc.
  • Nojihigashi 7-4-38
  • Kusatsu
  • Shiga
  • 525-0058
  • Japan

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
4974TSE (The Tokyo Stock Exchange)YesCommon StockJPJPYDec 2004
TF2DB (Deutsche Boerse AG)YesCommon StockDEEURDec 2004

Biography

Takara Bio Inc., together with its subsidiaries, operates as a biotechnology company in Japan and internationally. It operates through Bioindustry and Gene Therapy segments. The company develops original r ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/11/16 20:37
End of Day Share Price2019/11/15 00:00
Earnings2019/09/30
Annual Earnings2019/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.